149 related articles for article (PubMed ID: 32325142)
1. Janus kinase inhibition in complement component 1 deficiency.
Wolf C; Brück N; Koss S; Griep C; Kirschfink M; Palm-Beden K; Fang M; Röber N; Winkler S; Berner R; Latz E; Günther C; Lee-Kirsch MA
J Allergy Clin Immunol; 2020 Dec; 146(6):1439-1442.e5. PubMed ID: 32325142
[No Abstract] [Full Text] [Related]
2. Selective C1q deficiency in a patient with systemic lupus erythematosus.
Orihara T; Tsuchiya K; Yamasaki S; Furuya T
Br J Dermatol; 1987 Aug; 117(2):247-54. PubMed ID: 3498507
[TBL] [Abstract][Full Text] [Related]
3. Inborn C1r dificiency with a mild lupus-like syndrome.
Rich KC; Hurley J; Gewurz H
Clin Immunol Immunopathol; 1979 May; 13(1):77-84. PubMed ID: 455800
[No Abstract] [Full Text] [Related]
4. [C1q deficiency in systemic lupus erythematosus].
Garred P; Morling N
Ugeskr Laeger; 1999 Oct; 161(42):5809. PubMed ID: 10578698
[No Abstract] [Full Text] [Related]
5. Complement deficiency and autoimmunity.
Sullivan KE
Curr Opin Pediatr; 1998 Dec; 10(6):600-6. PubMed ID: 9848020
[TBL] [Abstract][Full Text] [Related]
6. A novel JAK/ROCK inhibitor, CPL409116, demonstrates potent efficacy in the mouse model of systemic lupus erythematosus.
Dulak-Lis M; Bujak A; Gala K; Banach M; Kędzierska U; Miszkiel J; Hucz-Kalitowska J; Mroczkiewicz M; Stypik B; Szymczak K; Gunerka P; Dubiel K; Zygmunt BM; Wieczorek M; Pieczykolan JS
J Pharmacol Sci; 2021 Apr; 145(4):340-348. PubMed ID: 33712286
[TBL] [Abstract][Full Text] [Related]
7. The Jakinibs in systemic lupus erythematosus: progress and prospects.
Mok CC
Expert Opin Investig Drugs; 2019 Jan; 28(1):85-92. PubMed ID: 30462559
[TBL] [Abstract][Full Text] [Related]
8. Management of cutaneous lupus erythematosus with Janus kinase inhibitor therapy: An evidence-based review.
Abduelmula A; Sood S; Mufti A; Hinek A; Yeung J
J Am Acad Dermatol; 2023 Jul; 89(1):130-131. PubMed ID: 36935014
[No Abstract] [Full Text] [Related]
9. Persistent Clq deficiency in a patient with a systemic lupus erythematosus-like syndrome.
Wara DW; Reiter EO; Doyle NE; Gewurz H; Ammann AJ
J Pediatr; 1975 May; 86(5):743-5. PubMed ID: 1079532
[No Abstract] [Full Text] [Related]
10. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial.
Wallace DJ; Furie RA; Tanaka Y; Kalunian KC; Mosca M; Petri MA; Dörner T; Cardiel MH; Bruce IN; Gomez E; Carmack T; DeLozier AM; Janes JM; Linnik MD; de Bono S; Silk ME; Hoffman RW
Lancet; 2018 Jul; 392(10143):222-231. PubMed ID: 30043749
[TBL] [Abstract][Full Text] [Related]
11. Inhaled Janus Kinase (JAK) inhibitors for the treatment of asthma.
Zak M; Dengler HS; Rajapaksa NS
Bioorg Med Chem Lett; 2019 Oct; 29(20):126658. PubMed ID: 31522830
[TBL] [Abstract][Full Text] [Related]
12. Deficiency of the first component of human complement.
Reid KB
Immunodefic Rev; 1989; 1(3):247-60. PubMed ID: 2561058
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of JAK 1/2 inhibition in the treatment of diffuse non-scarring alopecia due to systemic lupus erythematosus.
Maeshima K; Shibata H
Ann Rheum Dis; 2020 May; 79(5):674-675. PubMed ID: 31900301
[No Abstract] [Full Text] [Related]
14. Cutaneous manifestations of complement deficiencies.
Lipsker D; Hauptmann G
Lupus; 2010 Aug; 19(9):1096-106. PubMed ID: 20693203
[TBL] [Abstract][Full Text] [Related]
15. Familial deficiency of two subunits of the first component of complement. C1r and C1s associated with a lupus erythematosus-like disease.
Lee SL; Wallace SL; Barone R; Blum L; Chase PH
Arthritis Rheum; 1978; 21(8):958-67. PubMed ID: 737019
[TBL] [Abstract][Full Text] [Related]
16. Lupus diseases associated with hereditary and acquired deficiencies of complement.
Agnello V
Springer Semin Immunopathol; 1986; 9(2-3):161-78. PubMed ID: 3544278
[No Abstract] [Full Text] [Related]
17. Complement deficiency states.
Agnello V
Medicine (Baltimore); 1978 Jan; 57(1):1-23. PubMed ID: 337041
[No Abstract] [Full Text] [Related]
18. Pathogenic and Therapeutic Relevance of JAK/STAT Signaling in Systemic Lupus Erythematosus: Integration of Distinct Inflammatory Pathways and the Prospect of Their Inhibition with an Oral Agent.
Alunno A; Padjen I; Fanouriakis A; Boumpas DT
Cells; 2019 Aug; 8(8):. PubMed ID: 31443172
[TBL] [Abstract][Full Text] [Related]
19. Targeting JAK-STAT signal transduction in IBD.
Soendergaard C; Bergenheim FH; Bjerrum JT; Nielsen OH
Pharmacol Ther; 2018 Dec; 192():100-111. PubMed ID: 30048708
[TBL] [Abstract][Full Text] [Related]
20. Supporting allergen-specific immunotherapy by inhibition of Janus kinases.
Gutermuth J; Schmidt-Weber CB; Blank S
Allergy; 2019 Sep; 74(9):1814-1816. PubMed ID: 30953592
[No Abstract] [Full Text] [Related]
[Next] [New Search]
